These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1615219)
1. LH-RH agonists in the treatment of ovarian cancer. Emons G; Ortmann O; Pahwa GS; Oberheuser F; Schulz KD Recent Results Cancer Res; 1992; 124():55-68. PubMed ID: 1615219 [No Abstract] [Full Text] [Related]
2. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Yano T; Pinski J; Radulovic S; Schally AV Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926 [TBL] [Abstract][Full Text] [Related]
5. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. Halmos G; Schally AV; Kahan Z Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548 [TBL] [Abstract][Full Text] [Related]
6. Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp-6-LH-RH: a preliminary report. Pour PM; Redding TW; Paz-Bouza JI; Schally AV Cancer Lett; 1988 Jul; 41(1):105-10. PubMed ID: 2968836 [TBL] [Abstract][Full Text] [Related]
7. Primary and salvage therapy with LH-RH analogues in ovarian cancer. Emons G; Schulz KD Recent Results Cancer Res; 2000; 153():83-94. PubMed ID: 10626291 [TBL] [Abstract][Full Text] [Related]
8. Growth inhibitory effect of LH-RH analogs on human breast cancer cells. Scambia G; Panici PB; Baiocchi G; Perrone L; Gaggini C; Iacobelli S; Mancuso S Anticancer Res; 1988; 8(1):187-90. PubMed ID: 2965864 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Manetta A; Gamboa-Vujicic G; Paredes P; Emma D; Liao S; Leong L; Asch B; Schally A Fertil Steril; 1995 Feb; 63(2):282-7. PubMed ID: 7843432 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists. Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693 [TBL] [Abstract][Full Text] [Related]
11. Direct antitumor effects of LH-RH analogs. Foekens JA; Klijn JG Recent Results Cancer Res; 1992; 124():7-17. PubMed ID: 1615221 [No Abstract] [Full Text] [Related]
12. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826 [TBL] [Abstract][Full Text] [Related]
14. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. Tang X; Yano T; Osuga Y; Matsumi H; Yano N; Xu J; Wada O; Koga K; Kugu K; Tsutsumi O; Schally AV; Taketani Y J Clin Endocrinol Metab; 2002 Aug; 87(8):3721-7. PubMed ID: 12161501 [TBL] [Abstract][Full Text] [Related]
15. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Miyazaki M; Schally AV; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P Am J Obstet Gynecol; 1999 May; 180(5):1095-103. PubMed ID: 10329861 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Sharoni Y; Bosin E; Miinster A; Levy J; Schally AV Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1648-51. PubMed ID: 2646641 [TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Bruckner HW; Motwani BT Am J Obstet Gynecol; 1989 Nov; 161(5):1216-8. PubMed ID: 2511761 [TBL] [Abstract][Full Text] [Related]
19. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223 [TBL] [Abstract][Full Text] [Related]
20. Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas. Cortes-Prieto J; Lledo A; Avila C; Cortes-Garcia L; D'Acunto A; Luisi M; Comaru-Schally AM; Schally AV Int J Fertil; 1987; 32(4):290-7. PubMed ID: 2887526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]